Related Experiment Video

Updated: May 27, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Impact of insulin pumps on glycaemic control in a pump-naïve paediatric regional population

Martin de Bock1, Alistair Jan Gunn, Jean-Ann Holt

  • 1The Liggins Institute Department of Physiology, University of Auckland, Auckland, New Zealand. m.debock@auckland.ac.nz

Journal of Paediatrics and Child Health
|November 17, 2011
PubMed

Insights

Insulin-pump therapy improved HbA1c and reduced severe hypoglycemia in children with type 1 diabetes (T1DM). This safe and effective treatment offers sustained benefits for pediatric diabetes management.

Area of Science:

  • Paediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Type 1 diabetes mellitus (T1DM) requires intensive management in children.
  • Insulin-pump therapy is an alternative to multiple daily injections.

Purpose of the Study:

  • To evaluate the clinical impact of insulin-pump therapy in a regional paediatric diabetes service.
  • To assess safety and efficacy in a pump-naïve pediatric population.

Main Methods:

  • Retrospective analysis of children with T1DM from 2002-2008.
  • Comparison of insulin-pump users with the general T1DM population and matched non-pump controls.
  • Data sourced from the Starship paediatric diabetes database.

Main Results:

  • Insulin-pump therapy improved HbA1c by -0.3%/year for up to 3 years.
  • Non-pump controls showed a trend towards higher HbA1c (+0.2%/year).
  • Severe hypoglycaemia risk decreased significantly (27 to 5 events/100 patient years) with pump use; diabetic ketoacidosis rates remained low.

Conclusions:

  • Insulin-pump therapy is safe and effective for children with T1DM in a regional paediatric setting.
  • Sustained improvements in HbA1c and reduced risk of hypoglycaemia were observed.
  • The therapy demonstrated significant clinical benefits for a pump-naïve paediatric population.
Abstract

More Related Videos

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas04:41

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...